Business Wire

HCL-FOUNDATION

16.2.2021 11:37:15 CET | Business Wire | Press release

Share
HCL Foundation Continues Commitment to Enhance Rural Lives; Announces INR 16.5 Crore ($2.27 Million) Grant to NGOs in Sixth Edition of HCL Grant

HCL Foundation, the corporate social responsibility arm of HCL Technologies Ltd., today announced the winners of the sixth round of the HCL Grant, a flagship program dedicated to strengthening India’s “fifth estate” of NGOs working towards nation building.

The three NGOs, one each in the development areas of environment, health, and education, will each receive a grant of INR 5 crore ($685,000) for a three to five-year project. In addition, two finalists in each category will receive a one-year grant of INR 25 lakhs ($34,000), making a total grant of INR 16.5 crore.

HCL Foundation, which this year celebrates a decade of building strong and robust communities, is committed to contributing to the nation’s growth curve. Under its HCL Grant program, the Foundation has so far committed a more than INR 60 crore ($8.26 Million), excluding this year’s grants. Recognized as one of the most sought-after validations amongst NGO ecosystems in India, the HCL Grant has in the past five years reached over 733,000 beneficiaries. The Grant aims to touch the lives of at least 1.72 million people in 8,598 villages in 70 districts across 18 states and two union territories of India.

The winning NGOs of HCL Grant 2021 were:

  • Saahas (Environment)
  • India Health Action Trust (Health)
  • Child Rights and You (Education)

The NGOs were chosen after an 8-month review of thousands of applications by an eminent jury, monitored and audited by Grant Thornton, the governance partner of HCL Grant. The jury consisted of: Ms. Robin Abrams, Director, HCL Technologies, and Chairperson of the jury; Mr. Suresh Narayanan, Chairman and Managing Director, Nestle India Limited; Mr. B. S. Baswan, former Director, Indian Institute of Public Administration, and former Secretary, Human Resource Development ministry; Ms. Pallavi Shroff, Managing Partner, Shardul Amarchand Mangaldas & Co. law firm; Dr. Richard Lariviere, President Emeritus, Field Museum (Chicago), and former President, University of Oregon; and Mr. Shiv Nadar, Founder of HCL, Chief Strategy Officer of HCL Technologies, and Founder and Chairman of the Shiv Nadar Foundation.

“The past year was a unique year of resilience and transformation that taught us how to transcend barriers and keep going even in the face of adversity,” said Ms. Abrams. “Despite the pandemic, the robustness demonstrated by our NGO partners, experts, jury members and the entire team is commendable. The passion and zeal of our NGO partners to bring in scalable and replicable solutions have created systemic shifts across geographies, lending velocity to the sustainable development agenda. The winners and finalists of this year’s Grant also have significant stories to tell, with visible on-the-ground impact. My best wishes to these NGOs, who are addressing some of the most pressing issues in the key development categories of environment, health, and education in the most remote corners of the country.”

Ms. Nidhi Pundhir, Director, HCL Foundation, said: “The year 2020 has been both special and unusual. Special, in that the Foundation is completing ten years of facilitating high-impact, sustainable socio-economic development in rural India. Unusual, in that the NGOs we support had to deal with unprecedented challenges posed by the pandemic and various natural disasters, while initiating and implementing their developmental projects. What is inspiring about these NGOs is that they are treating COVID-19 as the ‘new normal’ and are continuing with their path-breaking projects without a pause, creating a much-needed last-mile support framework.”

On the occasion of the grant awards, the HCL Foundation released “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education,” a compendium featuring the top 30 NGOs selected in the sub-jury round, as well as the previous year’s winning NGOs.

For more information please visit www.hclfoundation.org/hcl-grant

Link:

ClickThru

Social Media:

https://www.facebook.com/HCLTechnologies

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye